HomeAI · summaries
Storia in 2 fonti
An AI drug specialist zeroes in on rare forms of obesity
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
An AI drug specialist zeroes in on rare forms of obesity
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm…
- ·
endpoints.news
Superluminal secures $60M for Phase 1 of genetic obesity drug
Superluminal Medicines raises $60M Series B for Phase 1 trials of MC4R obesity drug, backed by investors including Eli Lilly, RA Capital and Nvidia's VC arm.